BioHarvest Sciences (BHST)
NASDAQ:BHST
Top Page
BioHarvest Sciences
(NASDAQ:BHST)
Select Model
Select Model
Rating:45Neutral
Price Target:
$5.50
▼(-51.24% Downside)
Action:ReiteratedDate:12/30/25
The score is held down primarily by weak financial performance (ongoing net losses, negative operating/free cash flow, and elevated leverage) and bearish technicals (below key moving averages with negative MACD). The latest earnings call adds support via strong revenue growth, improving gross margins, and guidance pointing toward adjusted EBITDA breakeven, but valuation remains constrained by unprofitability and no dividend.
Positive Factors
Proprietary plant‑cell cultivation platform
BioHarvest’s patented plant‑cell cultivation technology is a durable competitive asset that enables standardized, scalable production of botanical bioactives. This creates barriers to entry, supports CDMO services and branded product consistency, and underpins long-term differentiation in nutraceuticals.
Negative Factors
Negative operating and free cash flow
Persistent negative operating and free cash flow indicate the business is still cash‑consumptive, requiring ongoing external funding until margins and working capital convert to positive cash generation. This constrains strategic flexibility and increases funding risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary plant‑cell cultivation platform
BioHarvest’s patented plant‑cell cultivation technology is a durable competitive asset that enables standardized, scalable production of botanical bioactives. This creates barriers to entry, supports CDMO services and branded product consistency, and underpins long-term differentiation in nutraceuticals.
Read all positive factors
BioHarvest Sciences (BHST) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$97.87M
Dividend YieldN/A
Average Volume (3M)78.84K
Price to Earnings (P/E)―
Beta (1Y)0.70
Revenue Growth45.88%
EPS Growth43.12%
CountryUS
Employees87
SectorConsumer Defensive
Sector Strength42
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)-0.14
Shares Outstanding22,654,290
10 Day Avg. Volume86,360
30 Day Avg. Volume78,844
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)75.25
Price to Sales (P/S)3.97
P/FCF Ratio-10.51
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue2.57
Enterprise Value/Gross Profit4.34
Enterprise Value/Ebitda-18.24
Forecast
1Y Price Target
$10.00Price Target Upside-11.35% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.11
Revenue Forecast (FY)$47.47M
BioHarvest Sciences Business Overview & Revenue Model
Company Description
BioHarvest Sciences (BHST) is a biotechnology company specializing in the development and commercialization of innovative plant-based products for the health and wellness sectors. The company leverages its proprietary technology to produce high-qu...
How the Company Makes Money
BioHarvest Sciences generates revenue primarily through the sale of its proprietary plant-based products, including dietary supplements and nutraceuticals. The company has established key partnerships with manufacturers and distributors in the hea...
BioHarvest Sciences Earnings Call Summary
Earnings Call Date:Nov 13, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 31, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted strong revenue growth, particularly in the CDMO segment, and successful capital raising efforts that fortified the company's balance sheet. However, challenges remain with ongoing net losses and increased operating expenses. The sentiment is balanced due to significant achievements and challenges.Positive Updates
Significant Revenue Growth
Total revenues increased 39% year-over-year to $9.1 million, driven by sustained momentum in core VINIA capsules and the expanding success of the VINIA Inside product portfolio.
Negative Updates
Continued Net Losses
Net losses for Q3 2025 totaled $2.5 million, slightly improved from a net loss of $2.7 million in the same quarter of the previous year.
Read all updates
Q3-2025 Updates
Positive
Negative
Significant Revenue Growth
Total revenues increased 39% year-over-year to $9.1 million, driven by sustained momentum in core VINIA capsules and the expanding success of the VINIA Inside product portfolio.
Read all positive updates
Company Guidance
In the third quarter of 2025, BioHarvest Sciences reported a 39% year-over-year revenue increase to $9.1 million, aligning with its guidance, and approached its goal of achieving adjusted EBITDA breakeven. The company's U.S. VINIA active user base surpassed 75,000, contributing to a 30% growth in the products division. Core VINIA capsules accounted for 88% of product revenues, with new products like VINIA 2X Formula Chews driving approximately 30% of growth. The CDMO business, significantly bolstered by a new partnership with Saffron Tech, represented about 25% of the quarterly revenue growth. Gross profit margins increased to 61%, reflecting benefits from scale, while total operating expenses rose slightly to $6.5 million due to increased marketing and CDMO division expenses. BioHarvest also strengthened its balance sheet, securing a $19.9 million institutional equity financing, positioning the company to expand its direct-to-consumer and CDMO operations. Looking ahead, the company anticipates fourth-quarter revenues between $9 million and $9.5 million, with adjusted EBITDA nearing breakeven.BioHarvest Sciences Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
28
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.72M | 25.19M | 12.67M | 5.50M | 2.10M | 396.00K |
| Gross Profit | 19.37M | 13.94M | 5.63M | 1.22M | 670.00K | 138.00K |
| EBITDA | -4.61M | -9.72M | -9.76M | -9.13M | -8.64M | -5.77M |
| Net Income | -11.89M | -12.91M | -12.56M | -11.24M | -9.83M | -6.58M |
Balance Sheet | ||||||
| Total Assets | 35.19M | 25.00M | 15.00M | 9.39M | 10.21M | 5.30M |
| Cash, Cash Equivalents and Short-Term Investments | 10.97M | 2.39M | 5.36M | 1.74M | 4.12M | 1.78M |
| Total Debt | 19.84M | 13.82M | 22.34M | 10.56M | 2.66M | 2.71M |
| Total Liabilities | 27.45M | 23.67M | 29.86M | 15.32M | 7.35M | 7.60M |
| Stockholders Equity | 7.74M | 1.33M | -14.85M | -5.93M | 2.85M | -2.29M |
Cash Flow | ||||||
| Free Cash Flow | -10.07M | -9.52M | -10.00M | -10.50M | -8.43M | -4.05M |
| Operating Cash Flow | -8.00M | -6.68M | -8.52M | -9.24M | -6.79M | -3.88M |
| Investing Cash Flow | -2.07M | -3.03M | -1.47M | -1.26M | -1.64M | -173.00K |
| Financing Cash Flow | 18.49M | 6.78M | 13.56M | 8.14M | 10.77M | 4.93M |
BioHarvest Sciences Technical Analysis
Neutral
11.28
Price Trends
4.67
Negative
5.51
Negative
7.06
Negative
Market Momentum
-0.10
Negative
46.25
Neutral
26.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BHST, the sentiment is Neutral. The current price of 11.28 is above the 20-day moving average (MA) of 4.35, above the 50-day MA of 4.67, and above the 200-day MA of 7.06, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 46.25 is Neutral, neither overbought nor oversold. The STOCH value of 26.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BHST.
BioHarvest Sciences Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $91.23M | 2.45 | 11.71% | 3.93% | -8.09% | -15.28% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | $358.78M | -3.79 | -36.02% | ― | 159.45% | 8.59% | |
51 Neutral | $127.90M | -1.47 | -813.95% | ― | -37.13% | 40.47% | |
48 Neutral | $132.09M | 811.87 | -0.04% | ― | -33.41% | 81.19% | |
45 Neutral | $97.87M | -16.31 | -1198.89% | ― | 45.88% | 43.12% | |
41 Neutral | $118.40M | -4.42 | -193.06% | ― | ― | 99.21% |
* Consumer Defensive Sector Average
BHST
BioHarvest Sciences
4.32
-2.13
-33.02%
AGEN
Agenus
3.44
1.78
107.23%
SGMO
Sangamo Biosciences
0.34
-0.51
-59.86%
HURA
TuHURA Biosciences
1.95
-1.67
-46.13%
IH
iHuman
1.79
-0.49
-21.71%
PRE
Prenetics Group
21.32
17.51
459.58%
BioHarvest Sciences Corporate Events
BioHarvest Sciences Reports Strong Financial Position in Q3 2025
Nov 13, 2025
BioHarvest Sciences Inc. has released its unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2025. The financial report highlights a significant increase in cash and cash equivalents fro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.